Saturday, December 2

5:00 p.m.–6:00 p.m. Welcome and Opening Keynote
Promenades West, East and Salons I-III

The landscape of alterations in metastatic prostate cancer
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

6:00 p.m.–8:00 p.m. Welcome Reception

Sunday, December 3

7:00 a.m.–8:00 a.m. Breakfast
East Foyer, Marvin Gardens Lobby & Marvin Gardens Patio

8:00 a.m.–10:00 a.m. Plenary Session 1: Translating Prostate Cancer Genomics
Session Chair: Mark A. Rubin, University of Bern Department for BioMedical Research, Bern, Switzerland and Weill Cornell Medicine, New York, NY
Promenades West, East and Salons I-III

Prostate cancer: DNA-based risk assessment
William B. Isaacs, Johns Hopkins Hospital, Baltimore, MD

Differential impact of RB pathway status on E2F1 reprogramming and disease progression in human prostate cancer
Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA

Clinical and genomic resistance to existing and emerging therapies in prostate cancer
Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, MA

Synthesis and evaluation of structure-activity based derivatives of ERGi-USU, a selective inhibitor for ERG-positive prostate cancer cells*
Ahmed A. Mohamed, Uniformed Services University of the Health Sciences, Bethesda, MD

Differential impact of RB status on E2F1 reprogramming in human cancer*
Christopher McNair, Thomas Jefferson University, Philadelphia, PA

10:00 a.m.–10:30 a.m. Break
Promenade Foyer

*Short talks from proffered abstracts
10:30 a.m.–12:30 p.m. Plenary Session 2: Prostate Cancer Behavior—Distinguishing the Tigers from the Kittens
Session Chair: Himisha Beltran, Weill Cornell Medical College, New York, NY
Promenades West, East and Salons I-III

Emerging therapeutic strategies for androgen-indifferent prostate cancer
Himisha Beltran

The role of imaging in helping us to discriminate clinically significant prostate cancer from insignificant disease
Mark Emberton, University College London Hospitals, London, United Kingdom

Title to be announced
Felix Y. Feng, University of California San Francisco, San Francisco, CA

Radio-resistance of PTEN-deficient prostate tumors is enhanced by treatment-induced chemokine signaling and is associated with biochemical recurrence and development of metastasis*
Chris W.D. Armstrong, Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom

Oncogenic convergence of normal human prostate epithelial cells to a small cell neuroendocrine phenotype*
Jung Wook Park, University of California Los Angeles, Los Angeles, CA

12:30 p.m.–2:30 p.m. Lunch on Own

2:30 p.m.–4:30 p.m. Plenary Session 3: Roundtable on the Clinical Development of Biomarkers—Do We Need Better Biomarkers to Identify Higher-Risk, Locally Advanced Disease?
Moderator: Lorelei A. Mucci, Harvard School of Public Health, Boston, MA
Promenades West, East and Salons I-III

Introduction
Lorelei A. Mucci

Early detection of high-risk localized prostate cancer
Scott A. Tomlins, University of Michigan Medical School, Ann Arbor, MI

Early, highly specific risk stratification for lethal prostate cancer using a prespecified statistical model based on four Kallikrein markers in blood
Hans G. Lilja, Memorial Sloan Kettering Cancer Center, New York, NY

Comprehensive transcriptomic profiling challenges the robustness of prostate cancer prognostic signatures to multifocality*
Daniel H. Hovelson, University of Michigan, Ann Arbor, MI

Whole blood assay for rapid detection of AR-v7 in metastatic castration-resistant prostate cancer: No correlation with response to androgen-axis targeting agents*
Sarah To, Monash University, Melbourne, VIC, Australia

4:30 p.m.–6:30 p.m. Reception and Poster Session A
Salons IV-VI and Marvin Gardens and Marvin Gardens Patio

*Short talks from proffered abstracts
Monday, December 4

7:00 a.m.–8:00 a.m.  Breakfast
East Foyer, Marvin Gardens Lobby and Marvin Gardens Patio

8:00 a.m.–10:00 a.m.  Plenary Session 4: Risk and Screening—Where Next?
Session Chair: Freddie C. Hamdy, University of Oxford, Oxford, United Kingdom
Promenades West, East and Salons I-III

Risk and appropriate screening of African-Americans for prostate cancer
Isaac J. Powell, Barbara Ann Karmanos Cancer Institute, Detroit, MI

Germline genetic testing in prostate cancer
Colin Pritchard, University of Washington, Seattle, WA

The ProtecT study and early detection: What have we learnt?
Freddie C. Hamdy

Does coffee consumption confer survival benefits among men diagnosed with prostate cancer? A large prospective analysis in the Health Professionals Follow-up Study*
Cindy Zhou, Harvard T. H. Chan School of Public Health, Boston, MA

The past, current, and future incidence rates and burden of metastatic prostate cancer in the United States*
Michael Cook, National Cancer Institute, Rockville, MD

10:00 a.m.–10:30 a.m.  Break
Promenade Foyer

10:30 a.m.–12:30 p.m.  Plenary Session 5: Novel Therapeutic Strategies and Drug Targets
Session Chair: Johann de Bono, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Promenades West, East and Salons I-III

Improving prostate cancer care through novel therapeutic strategies
Johann de Bono

Identification of synthetic lethal dependencies in CRPC
Myles A. Brown, Dana-Farber Cancer Institute, Boston, MA

Targeting oligometastatic disease in prostate cancer
Kenneth J. Pienta, Johns Hopkins University School of Medicine, Baltimore, MD

Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer*  (Not CME accredited)
Nigel Brooks, CellCentric Ltd., Cambridge, United Kingdom

A highly potent novel class of P160-SRC inhibitors for the treatment of castration-resistant prostate cancer*
Salma Kaochar, Baylor College of Medicine, Houston, TX

*Short talks from proffered abstracts
12:30 p.m.–2:30 p.m.  
**Lunch and Poster Session B**
Salons IV-VI and Marvin Gardens and Marvin Gardens Patio

2:30 p.m.–4:30 p.m.  
**Plenary Session 6: DNA Repair and Prostate Cancer**
*Session Chair: Alan D. D'Andrea*, Dana-Farber Cancer Institute, Boston, MA
*Promenades West, East and Salons I-III*

- **Multimodal tumor genomics and the microenvironment:**  
  Annotating DNA repair and aggressive prostate cancer
  Robert G. Bristow, University Health Network Princess Margaret Hospital, Toronto, ON, Canada

- **PARP inhibitor resistance in prostate cancer**
  Alan D. D’Andrea

- **Sensitivity and resistance biomarkers to PARP inhibitors in mCRPC**
  Joaquin Mateo, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

- **An automated tissue staining and quantitative digital image analysis pipeline for quantification of DNA damage repair at the single-cell level**
  Beatrice Knudsen, Cedars-Sinai Medical Center, Los Angeles, CA

- **High-risk pathologic and genomic features of BRCA2-mutant prostate cancer**
  Laura H. Porter, Monash University, Clayton, VIC, Australia

4:30 p.m.–5:30 p.m.  
**Hot Topics in Prostate Cancer Research: Late-Breaking Results**
*Session Chair: Elin Thysell*, Department of Medical Biosciences, Pathology, Umea University, Umea, Sweden
*Promenades West, East and Salons I-III*

- **Prostate cancer neoadjuvant intensive androgen-deprivation therapy selects for tumor foci with diverse oncogenic alterations**
  Adam G. Sowalsky, National Cancer Institute, Bethesda, MD

- **Stem cell-directed pan-cancer analysis reveals a human adult stem cell signature that defines aggressive epithelial cancer subtypes**
  Bryan A. Smith, University of California Los Angeles, Los Angeles, CA

- **Clinically relevant molecular subgroups of prostate cancer bone metastases**
  Elin Thysell

- **Genomic variations associated with prostate cancer in large cohort of African American men**
  Walter Rayford, The Urology Group LLC, Memphis, TN

5:30 p.m.  
**Evening Off**

*Short talks from proffered abstracts*
Tuesday, December 5

7:00 a.m.–8:00 a.m.  Breakfast
*East Foyer, Marvin Gardens Lobby and Marvin Gardens Patio*

8:00 a.m.–10:00 a.m.  Plenary Session 7:  Alternate Mechanisms of Resistance
*Session Chair: Wassim Abida, Memorial Sloan Kettering Cancer Center, New York, NY*
*Promenades West, East and Salons I-III*

**Lineage plasticity in antiandrogen resistance**
Wassim Abida

**AR is ablated: Now what? Targeting the double-negative phenotype**
Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA

**Phenotype plasticity: A novel mechanism of targeted therapy resistance**
Mark A. Rubin, University of Bern Department for BioMedical Research, Bern, Switzerland and Weill Cornell Medicine, New York, NY

**Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy**
Alastair Davies, Vancouver Prostate Centre, Vancouver, BC, Canada

**Drug response variability between luminal and basal prostate cancer tumors**
Robert Den, Thomas Jefferson University, Philadelphia, PA

10:00 a.m.–10:30 a.m.  Break
*Promenade Foyer*

10:30 a.m.–12:30 p.m.  Plenary Session 8: Immunotherapy and Prostate Cancer
*Session Chair: Andrea Alimonti, Institute of Oncology Research, Bellinzona, Switzerland*
*Promenades West, East and Salons I-III*

**Targeting tumor-infiltrating myeloid cells for prostate cancer therapy**
Andrea Alimonti

**Using genomics to unravel the immune landscape of prostate cancer**
Olivier Elemento, Weill Cornell Medical College, New York, NY

**Making immunotherapy work in prostate cancer**
James L. Gulley, National Cancer Institute, Bethesda, MD

**PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model**
Jenessa Barbara Smith, Poseida Therapeutics, San Diego, CA

*Short talks from proffered abstracts*

12:30 p.m.–1:30 p.m.  Closing Keynote Presentation

**Impressions of a new NCI Director**
Norman E. Sharpless, National Cancer Institute, Bethesda, MD

1:30 p.m.  Closing Remarks